Emendo Biotherapeutics
Agent40Agent Readiness: 40/100. Below median. Measured by StartupHub.ai. Median 41.Trust77Data Trust: 77/100. Above median. Measured by StartupHub.ai. Median 61.Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.
About
Emendo Biotherapeutics is a genome editing company focused on creating novel genetic medicines and cell therapies for patients suffering from severe diseases. Their approach leverages proprietary protein engineering and selection platforms to generate highly specific and potent CRISPR OMNI nucleases, aiming to overcome limitations of existing gene editing tools.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
Biopharmaceutical company developing novel therapies for rare and ultra-rare genetic diseases.
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
Also in this space
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Shares Healthcare, Biotech
Develops a computational model of the human body for drug discovery and development.
Shares Healthcare, Drug Discovery
AI-powered spatial biology platform for precision medicine and drug development.
Shares Healthcare, HealthTech
Precision oncology company developing cancer therapies guided by proprietary functional genomics.
Shares Healthcare, Genomics
Biotech company using AI and deep RNA analysis to predict cancer treatment response.
Shares Healthcare, Genomics
Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.
Shares Healthcare, HealthTech
Key facts
- Website
- emendobio.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2015
- Employees
- 41
- Total funding
- $61M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 15 Jan 2020 | Series B | $61M |
Tech stack
Detected on emendobio.com, last scanned 8 Sept 2026. Run your own scan
- Frontend
- Bootstrap
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
- Cookie consent
- OneTrust
Emendo Biotherapeutics scores 23. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Emendo Biotherapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Emendo Biotherapeutics is 77 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Emendo Biotherapeutics raised?
Emendo Biotherapeutics has raised a total of $61M in funding. The most recent round on record is Series B.
How many employees does Emendo Biotherapeutics have?
Emendo Biotherapeutics has approximately 41 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Emendo Biotherapeutics
